AXIM Biotechnologies, Inc. (AXIM) income statement
AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2024, quý kết thúc ngày Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
AXIM Biotechnologies, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2024
Profitability, TTM
- Gross margin
- –
- Operating margin
- -2490.3%
- Net margin
- -4452.1%
- Return on equity, FY2023
- 129.1%
Financial strength
- Current ratio
- 0.00
- Debt to equity
- -0.02
- Debt to assets
- 5.0%
- Cash to current liabilities
- 0.1%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?